Thromboembolism in neonates and infants: Impact of underlying diseases, prothrombotic risk factors and treatment modalities

Thrombosis Research

Volumn 115, Issue SUPPL., 2005, Pages 71-77

  Kurnik, K ^a   Duering, C ^a   Bidlingmaier, C ^a   Nowak Gottl U ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Factor II G20210A; Factor V G1691A; Lipoprotein (a); Neonatal stroke; Paediatric venous thrombosis

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; HEPARIN; HEPARINOID; RECOMBINANT HIRUDIN; STREPTOKINASE;

ARTERY THROMBOSIS; CARDIOVASCULAR RISK; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; ENVIRONMENTAL FACTOR; GENETIC POLYMORPHISM; GENETICS; HEMOSTASIS; HUMAN; LABORATORY TEST; MOTHER FETUS RELATIONSHIP; OUTCOMES RESEARCH; PEDIATRICS; PHYSICAL DISEASE BY BODY FUNCTION; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; SKIN TEMPERATURE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOGENESIS; TREATMENT CONTRAINDICATION; VEIN THROMBOSIS;

ANTICOAGULANTS; FEMALE; GENETIC SCREENING; HUMANS; INFANT; INFANT, NEWBORN; PREGNANCY; RISK FACTORS; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 12544256028     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (79)

1. Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. Pediatrics 1995;95:936-3.
2. Nowak-Göttl U, von Kries R, Göbel U. Neonatal symptomatic thromboembolism in Germany: twoyear survey. Arch Dis Child 1997;76:F163-F7.
3. Kuhle S, Massicotte P, Chan A, Mitchell L. A case series of 72 neonates with renal vein thrombosis. Data from the 1-800-NO-CLOTS Registry. Thromb Haemost 2004;92:729-3.
4. Nowak-Göttl U, Dübbers A, Kececioglu D, et al. Factor V Leiden, protein C and lipoprotein (a) in catheter related thrombosis in childhood-a prospective study. J Pediatr 1997;131:608-2.
5. Vitiello R, McCrindle BW, Nykanen D, et al. Complications associated with pediatric cardiac catheterization. J Am Col Cardiol 1998;32:1433-40.
6. Salonvaara M, Riikonen P, Kekomaki R, et al. Clinical symptomatic central venous catheterrelated deep venous thrombosis in newborns. Acta Paediatrica 1999;88:642-6.
7. Boo NY, Wong NC, Zulkifli SS, et al. Risk factors associated with umbilical vascular catheterassociated thrombosis in newborn infants. J Pediatr Child Health 1999;35:460-5.
8. Schwartz DS, Gettner PA, Konstantino MM, et al. Umbilical venous catheterization and the risk of portal vein thrombosis. J Pediatr 1997;131:760-2.
9. Sträter R, Vielhaber H, Kassenböhmer R, et al. U. Genetic risk factors of thrombophilia in ischaemic childhood stroke of cardiac origin. A prospective ESPED survey. Eur J Pediatr 1999;158:S122-5.
10. Schlegel N. Thromboembolic risks and complications in nephrotic children. Sem Thromb Haemost 1997;23:271-80.
11. Hagstrom JN, Walter J, Bluebond-Langner R, et al. Prevalence of the factor V Leiden mutation in children and neonates with thromboembolic disease. J Pediatr 1998;133:777-81.
12. Heller C, Schobess R, Kurnik K, et al. Abdominal venous thrombosis in neonates and infants: Role of prothrombotic risk factors - a multicentre case-control study. Br J Haematol 2000;111:534-9.
13. Revel-Vilk S, Chan A, Bauman M, Massicotte P. Prothrombotic conditions in an unselected cohort of children with venous thromboembolic disease. J Thromb Haemost 2003;1:915-21.
14. Gurgey A, Tekinalp G, Cinar A, Cakmak F. Symptomatic thrombosis in Turkish neonates. J Pediatr Hematol Oncol 2004;26:417-20.
15. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: Part 1. Thromb Haemost 1996;76:651-62.
16. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. PNAS 1993;90:1004-8.
17. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
18. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3Vuntranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
19. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine-β-synthase deficiency. Am J Hum Genet 1985;37:1-31.
20. Nowak-Göttl U, Junker R, Hartmeier M, et al. Increased lipoprotein (a) is an important risk factor for venous thrombosis in childhood. Circulation 1999;100:743-8.
21. Nowak-Göttl U, Sträter R, Heinecke A, et al. Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin and methylenetetrahydrofolate reductase are risk factors of ischaemic stroke in childhood. Blood 1999;94:3678-82.
22. Ehrenforth S, Junker R, Koch HG, et al. Multicentre evaluation of combined prothrombotic defects with thrombophilia in childhood. Eur J Pediatr 1999;158:S97-104.
23. Junker R, Koch HG, Auberger K, et al. Prothrombin G20210A gene mutation and further prothrombotic risk factors in childhood thrombophilia. Arterioscler Thromb Vasc Biol 1999;19:2568-72.
24. van Ommen CH, Heijboer H, Buller HR, Hirasing RA, Heijmans HS, Peters M. Venous thromboembolism in childhood: a prospective 2-year registry in The Netherlands. J Pediatr 2001;139:676-81.
25. Atasay B, Arsan S, Gunlemez A, Kemahli S, Akar N. Factor V Leiden and prothrombin gene 20210A variant in neonatal thromboembolism and in healthy neonates and adults: a study in a single center. Pediatr Hematol Oncol 2003; 20:627-34.
26. El-Karaksy H, El-Koofy N, El-Hawary M, et al. Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study. Ann Hemato 2004;83:712-5.
27. Swarte R, Appel I, Lequin M, van Mol C, Govaert P. Factor II gene(prothrombin G20210A)mutation and neonatal cerebrovenous thrombosis. Thromb Haemost 2004;92:719-21.
28. Duering C, Kosch A, Langer C, Thedieck S, Nowak-Göttl U. Total tissue factor pathway inhibitor is an independent risk factor for symptomatic paediatric venous thromboembolism and stroke. Thromb Haemost 2004;92:707-12.
29. Andrew M. Developmental hemostasis: Relevance to thromboembolic complications in pediatric patients. Thromb Haemost 1995;74:415-425.
30. Ries M, Klinge J, Rauch R. Age-related reference values for activation markers of the coagulation and fibrinolytic systems in children. Thromb Res 1997;85:341-4.
31. Cvirn G, Gallistl S, Muntean W. Effects of antithrombin and protein C on thrombin generation in newborn and adult plasma. Thromb Res 1999;93:183-90.
32. Andrew M, Schmidt B, Mitchell L, et al. Thrombin generation in newborn plasma is critically dependent on the concentration of prothrombin. Thromb Haemost 1990;63:27-30.
33. Ries M, Klinge J, Rauch R, et al. In vitro fibrinolysis after adding low doses of plasminogen activators and plasmin generation with and without oxidative inactivation of plasmin inhibitors in newborns and adults. J Ped Hematol Oncol 1996;18:346-51.
34. Salafia CM, Vintzileos AM, Silberman L, et al. Placental pathology of idiopathic intrauterine growth retardation at term. Am J Perinatol 1992;9:179-84.
35. Brenner B, Sarig G, Wiener Z, et al. Thrombophilic polymorphisms are common in women with foetal loss without apparent cause. Thromb Haemost 1999;82:6-9.
36. Dizon-Townson DS, Meline L, Nelson LM, et al. Foetal carriers of the factor V Leiden are prone to miscarriage and placental infarction. Am J Obstet Gynecol 1997;177:402-5.
37. Berg K, Roland B, Sande H. High Lp(a) lipoprotein level in maternal serum may interfere with placental circulation and cause foetal growth retardation. Clin Genet 1994;46:52-6.
38. Pabinger I, Grafenhofer H, Kaider A, et al. Preeclampsia and fetal loss in women with a history of venous thromboembolism. Arterioscler Thromb Vasc Biol 2001;21:874-9.
39. Göpel W, Kim D, Gortner L. Prothrombotic mutations as a risk factor for preterm birth. Lancet 1999;353:1411-2.
40. Verspyck E, Le Camp-Duchez V, Gravier A, et al. Small for gestational age infant in association with maternal prothrombin gene variant (nt 20210A). Eur J Obstet Gynecol Reprod Biol 1999;83:143-4.
41. Kries von R, Junker R, Oberle D, Kosch A, Nowak-Göttl U. Foetal growth restriction in children with prothrombotic risk factors. Thromb Haemost 2001;86:1012-6.
42. Kenet G, Maayan-Metzger A, Rosenberg N, et al. Thrombophilia does not increase risk for neonatal complications in preterm infants. Thromb Haemost 2003;90:823-8.
43. Mocan H, Beattie TJ, Murphy AV. Renal venous thrombosis in infancy: long-term follow-up. Pediatr Nephrol 1991;5:45-9.
44. Bökenkamp A, von Kries R, Nowak-Göttl U, et al. Neonatal renal venous thrombosis in Germany between 1992 and 1994: epidemiology, treatment and outcome. Eur J Pediatr 2000;159:44-8.
45. Kosch A, Kuwertz-Broking E, Heller C, Kurnik K, Schobess R, Nowak-Göttl U. Renal venous thrombosis in neonates: prothrombotic risk factors and long-term follow-up. Blood 2004;104:1356-60.
46. Vries de LS, Eken P, Groenendaal F, et al. Antenatal onset of haemorrhagic and/or ischaemic lesions in preterm infants: prevalence and associated obstetric variables. Arch Dis Child 1998;78:F51-6.
47. Kraus FT, Acheen VI. Fetal thrombotic vasculopathy in the placenta: cerebral thrombi and infarcts, coagulopathies, and cerebral palsy. Hum Pathol 1999;30:759-69.
48. Debus O, Koch HG, Kurlemann G, et al. Factor V Leiden and genetic defects of thrombophilia in childhood porencephaly. Arch Dis Child 1998;78:F121-4.
49. Govaets P, Matthys E, Zecic A, et al. Perinatal cortical infarction within middle cerebral artery trunks. Arch Dis Child 2000;82:F59-63.
50. Debus OM, Kosch A, Sträter R, Rossi R, Nowak-Göttl U. The factor V G1691A mutation is a risk for porencephaly: A case-control study. Ann Neurol 2004;56:287-90.
51. Vielhaber H, Ehrenforth S, Koch HG, et al. Cerebral venous thrombosis in infancy and childhood: role of genetic and acquired risk factors of thrombophilia. Eur J Pediatr 1998;157:555-60.
52. Riikonen RS, Vahtera EM, Kekomäki RM. Physiological anticoagulants and activated protein C resistance in childhood stroke. Acta Paediatr 1996;85:242-4.
53. Zenz W, Bodo Z, Plotho J, et al. Factor V Leiden and prothrombin gene G20210A variant in children with stroke. Thromb Haemost 1998;80:763-6.
54. Van Beynum IM, Smeitink JA, den Heijer M, et al. Hyperhomocysteinemia: a risk for ischaemic stroke in children. Circulation 1999;99:2070-2.
55. Kenet G, Sadetzki S, Murad H, et al. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischaemic stroke in children. Stroke 2000;31:1283-8.
56. Günther G, Junker R, Sträter R, et al. Symptomatic ischaemic stroke in full-term neonates: Role of acquired and genetic prothrombotic risk factors. Stroke 2000;31:246-51.
57. Laeson SE, Butler D, Enayat MS, Williams MD. Congenital thrombophilia and thrombosis: a study in a single centre. Arch Dis Child 1999;81:176-8.
58. Bonduel M, Hepner M, Sciuccati G, et al. Prothrombotic abnormalities in children with venous thromboembolism. J Pediatr Hematol Oncol 2000;22:66-72.
59. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: Part 2. Thromb Haemost 1996;76:824-34.
60. Manco-Johnson M, Abshire T, Jacobson L, Marlar R. Severe neonatal protein C deficiency: prevalence and thrombotic risk. J Pediatr 1991;119:793-8.
61. Manco-Johnson MJ, Nuss R, Key N, et al. Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans or thrombosis. J Pediatr 1996;128:319-23.
62. Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol 1990;12:95-104.
63. Häuseler M, Duyue D, Merz U, et al. The clinical outcome after inferior vena cava thrombosis in early infancy. Eur J Pediatr 1999;158:416-20.
64. De Schryver EL, Blom I, Braun KP, et al. Longterm prognosis of cerebral venous sinus thrombosis in childhood. Dev Med Child Neurol 2004;46:514-9.
65. Kurnik K, Kosch A, Sträter R, Schobess R, Heller C, Nowak-Göttl U; Childhood Stroke Study Group. Recurrent thromboembolism in infants and children suffering from symptomatic neonatal arterial stroke: a prospective follow-up study. Stroke 2003;34:2887-92.
66. Andrew M, Michelson AD, Bovill E, et al. Guidelines for antithrombotic therapy in pediatric patients. J Pediatr 1998;132:575-88.
67. Massicotte P, Adams M, Marzinotto V, et al. Low molecular weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996;128:313-18.
68. Dix D, Andrew M, Marzinotto V, et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr 2000;136:439-45.
69. Kirk CR, Qureshi SA. Streptokinase in the management of arterial thrombosis in infancy. Int J Cardiol 1989;25:15-20.
70. Nowak-Göttl U, Schwabe D, Schneider W, et al. Thrombolysis with recombinant tissue-type plasminogen activator in renal venous thrombosis in infancy. Lancet 1992;340:1005.
71. Wever ML, Liem KD, Geven WB, Tanke RB. Urokinase therapy in neonates with catheter related central venous thrombosis. Thromb Haemost 1995;73:180-5.
72. Farnoux C, Camard O, Pinquier D, et al. Recombinant tissue-type plasminogen activator therapy of thrombosis in 16 neonates. J Pediatr 1998;133:137-40.
73. Weiner GM, Castle VP, DiPietro MA, Faix RG. Successful treatment of neonatal arterial thrombosis with recombinant tissue plasminogen activator. J Pediatr 1998;133:133-6.
74. Nowak-Göttl U, Auberger K, Halimeh S, et al. Thrombolysis in newborns and infants. Thromb Haemost 1999;82:S112-6.
75. Manco-Johnson MJ, Nuss R, Krupski W, et al. Combined thrombolytic and anticoagulant therapy for venous thrombosis in children. J Pediatr 2000;136:446-53.
76. Monagle P, Adams M, Mahoney M, et al. Outcome of pediatric thromboembolic disease: a report from the Canadian childhood thrombophilia registry. Ped Res 2000;47:763-6.
77. Nowak-Göttl U, Junker R, Kreuz W, et al. Risk of recurrent thrombosis in children with combined prothrombotic risk factors. Blood 2001;97:858-62.
78. van Ommen CH, Heijboer H, van den Dool EJ, Hutten BA, Peters M. Pediatric venous thromboembolic disease in one single center: congenital prothrombotic disorders and the clinical outcome. J Thromb Haemost 2003;1:2516-22.
79. Goldenberg NA, Knapp-Clevenger R, Manco-Johnson MJ; Mountain States Regional Thrombophilia Group. Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children. N Engl J Med 2004;351:1081-8.